AIMS: Chloroquine, an anti-malarial quinoline, is structurally similar to quinidine. Both drugs have been shown to block ion channels. We tested the hypothesis that chloroquine's mode of interaction with the vestibule of the cytoplasmic domain of the inward rectifier potassium channel Kir2.1 makes it a more effective I(K1) blocker and anti-fibrillatory agent than quinidine. METHODS AND RESULTS: We used comparative molecular modelling and ligand docking of the three-dimensional structures of quinidine and chloroquine in the intracellular domain of Kir2.1. Simulations predicted that chloroquine effectively blocks potassium flow by binding at the centre of the ion permeation vestibule of Kir2.1. In contrast, quinidine binds the vestibular side, only partially blocking ion movement. We tested the modelling predictions in Kir2.1-expressing human embryonic kidney (HEK)-293 cells. The half-maximal inhibitory concentration for chloroquine block of I(K1) was 1.2 µM, while that of quinidine was 57 µM. Finally, we used optical mapping of Langendorff-perfused mouse hearts with cardiac-specific Kir2.1 up-regulation to compare the anti-fibrillatory effects of the drugs. In five of six hearts, 10 μM quinidine slowed the frequency but did not terminate the tachyarrhythmia. In five of five hearts, 10 μM chloroquine terminated the arrhythmia, restoring sinus rhythm. CONCLUSION: Quinidine only partially blocks I(K1). Chloroquine binds at the centre of the ion permeation vestibule of Kir2.1, which makes it a more effective I(K1) blocker and anti-fibrillatory agent than quinidine. Integrating the structural biology of drug-ion channel interactions with cellular electrophysiology and optical mapping is an excellent approach to understand the molecular mechanisms of anti-arrhythmic drug action and for drug discovery.
AIMS: Chloroquine, an anti-malarial quinoline, is structurally similar to quinidine. Both drugs have been shown to block ion channels. We tested the hypothesis that chloroquine's mode of interaction with the vestibule of the cytoplasmic domain of the inward rectifier potassium channel Kir2.1 makes it a more effective I(K1) blocker and anti-fibrillatory agent than quinidine. METHODS AND RESULTS: We used comparative molecular modelling and ligand docking of the three-dimensional structures of quinidine and chloroquine in the intracellular domain of Kir2.1. Simulations predicted that chloroquine effectively blocks potassium flow by binding at the centre of the ion permeation vestibule of Kir2.1. In contrast, quinidine binds the vestibular side, only partially blocking ion movement. We tested the modelling predictions in Kir2.1-expressing humanembryonic kidney (HEK)-293 cells. The half-maximal inhibitory concentration for chloroquine block of I(K1) was 1.2 µM, while that of quinidine was 57 µM. Finally, we used optical mapping of Langendorff-perfused mouse hearts with cardiac-specific Kir2.1 up-regulation to compare the anti-fibrillatory effects of the drugs. In five of six hearts, 10 μM quinidine slowed the frequency but did not terminate the tachyarrhythmia. In five of five hearts, 10 μM chloroquine terminated the arrhythmia, restoring sinus rhythm. CONCLUSION:Quinidine only partially blocks I(K1). Chloroquine binds at the centre of the ion permeation vestibule of Kir2.1, which makes it a more effective I(K1) blocker and anti-fibrillatory agent than quinidine. Integrating the structural biology of drug-ion channel interactions with cellular electrophysiology and optical mapping is an excellent approach to understand the molecular mechanisms of anti-arrhythmic drug action and for drug discovery.
Authors: Christian Wolpert; Rainer Schimpf; Carla Giustetto; Charles Antzelevitch; Jonathan Cordeiro; Robert Dumaine; Ramon Brugada; Kui Hong; Urs Bauersfeld; Fiorenzo Gaita; Martin Borggrefe Journal: J Cardiovasc Electrophysiol Date: 2005-01
Authors: Li Zhang; D Woodrow Benson; Martin Tristani-Firouzi; Louis J Ptacek; Rabi Tawil; Peter J Schwartz; Alfred L George; Minoru Horie; Gregor Andelfinger; Gregory L Snow; Ying-Hui Fu; Michael J Ackerman; G Michael Vincent Journal: Circulation Date: 2005-05-23 Impact factor: 29.690
Authors: Sami F Noujaim; Sandeep V Pandit; Omer Berenfeld; Karen Vikstrom; Marina Cerrone; Sergey Mironov; Michelle Zugermayr; Anatoli N Lopatin; José Jalife Journal: J Physiol Date: 2006-11-09 Impact factor: 5.182
Authors: Peter Milberg; Regina Tegelkamp; Nani Osada; Rainer Schimpf; Christian Wolpert; Günter Breithardt; Martin Borggrefe; Lars Eckardt Journal: J Cardiovasc Electrophysiol Date: 2007-06
Authors: Silvia G Priori; Sandeep V Pandit; Ilaria Rivolta; Omer Berenfeld; Elena Ronchetti; Amit Dhamoon; Carlo Napolitano; Justus Anumonwo; Marina Raffaele di Barletta; Smitha Gudapakkam; Giuliano Bosi; Marco Stramba-Badiale; José Jalife Journal: Circ Res Date: 2005-03-10 Impact factor: 17.367
Authors: Yoshio Takemoto; Diana P Slough; Gretchen Meinke; Christopher Katnik; Zachary A Graziano; Bojjibabu Chidipi; Michelle Reiser; Mohammed M Alhadidy; Rafael Ramirez; Oscar Salvador-Montañés; Steven Ennis; Guadalupe Guerrero-Serna; Marian Haburcak; Carl Diehl; Javier Cuevas; Jose Jalife; Andrew Bohm; Yu-Shan Lin; Sami F Noujaim Journal: FASEB J Date: 2018-01-05 Impact factor: 5.191
Authors: Panagiotis Xynogalos; Claudia Seyler; Daniel Scherer; Christoph Koepple; Eberhard P Scholz; Dierk Thomas; Hugo A Katus; Edgar Zitron Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2014-09-04 Impact factor: 3.000
Authors: Makarand Deo; Yanfei Ruan; Sandeep V Pandit; Kushal Shah; Omer Berenfeld; Andrew Blaufox; Marina Cerrone; Sami F Noujaim; Marco Denegri; José Jalife; Silvia G Priori Journal: Proc Natl Acad Sci U S A Date: 2013-02-25 Impact factor: 11.205